# Neoadjuvant Cetuximab, Fluorouracil, and Pelvic Irradiation in Treating Patients With Locally Advanced or Locally Recurrent Rectal Cancer

> **NCT00084773** · NA · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 28 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **BIOLOGICAL:** cetuximab
- **DRUG:** fluorouracil
- **PROCEDURE:** neoadjuvant therapy
- **RADIATION:** radiation therapy

## Key facts

- **NCT ID:** NCT00084773
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-03
- **Primary completion:** 2007-01
- **Final completion:** 2010-03
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2015-12-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00084773

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00084773, "Neoadjuvant Cetuximab, Fluorouracil, and Pelvic Irradiation in Treating Patients With Locally Advanced or Locally Recurrent Rectal Cancer". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00084773. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*